Global Genetic Obesity Drugs Market

Genetic Obesity Drugs Comprehensive Study by Type (Monogenic, Syndromic), Category (Class 1: BMI - 30 to < 35, Class 2: BMI - 35 to < 40, Class 3: BMI - > 40), Drug (Bupropion-naltrexone, Liraglutide, Orlistat, Phentermine-topiramate, Others), Distribution Channel (Hospitals pharmacy, Retail Pharmacy, Drug Stores, Online Pharmacy), End-User (Hospitals, Clinics, Diagnostic Centres, Government) Players and Region - Global Market Outlook to 2030

Genetic Obesity Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Genetic Obesity Drugs Market Overview:
Obesity is a global health concern that has negative consequences for all organ systems, resulting in increased disease and growing healthcare expenses. If criteria are met and more severe intervention is needed, people with obesity who are failing lifestyle therapy should be advanced to appropriate pharmacological treatment modalities, medical devices, and/or bariatric surgery. Obesity is caused by a chronic energy imbalance in which a person consumes more calories from food and drink than their body requires to power its metabolic and physical functions. Obesity has become more common in recent decades, owing to an obesogenic environment that provides easy access to high-calorie meals while limiting possibilities for physical activity. The obesity pandemic might be seen as a communal reaction to this situation. Obesity is a severe public health issue since it raises the risk of diabetes, heart disease, stroke, and other serious illnesses. As per latest study released by AMA Research, the Global Genetic Obesity Drugs market is expected to see growth rate of 9.0%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Growing Prevalence of Epigenetics in Treatment of Obesity

Market Growth Drivers:
Rise in Unhealthy and Junk Food Lifestyle and Increasing Diabetes Patients

Challenges:
Lack of Healthcare Infrastructure in Developing Nations and High Competition among Established Players

Restraints:
High Cost of Obesity Drugs

Opportunities:
Rising Opportunities in Emerging Economies

Competitive Landscape:
The demand for Genetic Obesity Drugs is increasing. The industry is segmented, but it is predicted to grow as rise in unhealthy lifestyle and increasing investment in R&D, among other factors, drive the market forward. Businesses in this sector face global competition from market leaders who control a large share of the market. Companies are differentiating their products from competition by employing environmentally friendly materials and manufacturing techniques. The Leading Players are engaging in strategic global expansion to maintain their Market Position.
Some of the key players profiled in the report are Pfizer (United States), Sanofi (France), Roche Holding AG (Switzerland), Regeneron Pharmaceuticals (United States), AstraZeneca (United Kingdom), Gilead Sciences (United States), Bristol Myers Squibb (United States), Novo Nordisk (Denmark), Rhythm Pharmaceuticals (United States) and PreveCeutical Medical (Canada). Additionally, following companies can also be profiled that are part of our coverage like EraCal Therapeutics (Switzerland), Phenomix Sciences (United States) and Antag Therapeutics (Denmark). Analyst at AMA Research see United States Players to retain maximum share of Global Genetic Obesity Drugs market by 2030. Considering Market by Type, the sub-segment i.e. Monogenic will boost the Genetic Obesity Drugs market. Considering Market by Category, the sub-segment i.e. Class 1: BMI - 30 to < 35 will boost the Genetic Obesity Drugs market. Considering Market by Drug , the sub-segment i.e. Bupropion-naltrexone will boost the Genetic Obesity Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospitals pharmacy will boost the Genetic Obesity Drugs market. Considering Market by End-User, the sub-segment i.e. Hospitals will boost the Genetic Obesity Drugs market.

Latest Market Insights:
In November 2021 Novo Nordisk had announced the acquisition of Dicerna Pharmaceuticals. The acquisition of Dicerna's ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk's existing research technology platforms, and it aligns with the company's strategy of using a diverse set of technology platforms that can be applied across all of Novo Nordisk's therapeutic focus areas.

On November 15, 2023, Novo Nordisk and Gründerzentrum für Medizin und Gesundheitstechnologie München (MGTM) partnered to launch the "NMD Innovation Hub Munich," focused on accelerating innovation in metabolic diseases like obesity.

What Can be Explored with the Genetic Obesity Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Genetic Obesity Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Genetic Obesity Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Genetic Obesity Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Genetic Obesity Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture and Capitalist, New entrants/investors, Analysts and Strategic Business Partners, Hospital, Clinics, Diagnostic Centres and End-use industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Monogenic
  • Syndromic

By Category
  • Class 1: BMI - 30 to < 35
  • Class 2: BMI - 35 to < 40
  • Class 3: BMI - > 40

By Drug
  • Bupropion-naltrexone
  • Liraglutide
  • Orlistat
  • Phentermine-topiramate
  • Others

By Distribution Channel
  • Hospitals pharmacy
  • Retail Pharmacy
  • Drug Stores
  • Online Pharmacy

By End-User
  • Hospitals
  • Clinics
  • Diagnostic Centres
  • Government

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Unhealthy and Junk Food Lifestyle
      • 3.2.2. Increasing Diabetes Patients
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Infrastructure in Developing Nations
      • 3.3.2. High Competition among Established Players
    • 3.4. Market Trends
      • 3.4.1. Growing Prevalence of Epigenetics in Treatment of Obesity
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genetic Obesity Drugs, by Type, Category, Drug , Distribution Channel, End-User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Genetic Obesity Drugs (Value)
      • 5.2.1. Global Genetic Obesity Drugs by: Category (Value)
        • 5.2.1.1. Class 1: BMI - 30 to < 35
        • 5.2.1.2. Class 2: BMI - 35 to < 40
        • 5.2.1.3. Class 3: BMI - > 40
      • 5.2.2. Global Genetic Obesity Drugs by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals pharmacy
        • 5.2.2.2. Retail Pharmacy
        • 5.2.2.3. Drug Stores
        • 5.2.2.4. Online Pharmacy
      • 5.2.3. Global Genetic Obesity Drugs by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Diagnostic Centres
        • 5.2.3.4. Government
      • 5.2.4. Global Genetic Obesity Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Genetic Obesity Drugs (Volume)
      • 5.3.1. Global Genetic Obesity Drugs by: Category (Volume)
        • 5.3.1.1. Class 1: BMI - 30 to < 35
        • 5.3.1.2. Class 2: BMI - 35 to < 40
        • 5.3.1.3. Class 3: BMI - > 40
      • 5.3.2. Global Genetic Obesity Drugs by: Distribution Channel (Volume)
        • 5.3.2.1. Hospitals pharmacy
        • 5.3.2.2. Retail Pharmacy
        • 5.3.2.3. Drug Stores
        • 5.3.2.4. Online Pharmacy
      • 5.3.3. Global Genetic Obesity Drugs by: End-User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Diagnostic Centres
        • 5.3.3.4. Government
      • 5.3.4. Global Genetic Obesity Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Australia
          • 5.3.4.2.6. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Genetic Obesity Drugs (Price)
  • 6. Genetic Obesity Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Holding AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Regeneron Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gilead Sciences (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novo Nordisk (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Rhythm Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PreveCeutical Medical (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Genetic Obesity Drugs Sale, by Type, Category, Drug , Distribution Channel, End-User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Genetic Obesity Drugs (Value)
      • 7.2.1. Global Genetic Obesity Drugs by: Category (Value)
        • 7.2.1.1. Class 1: BMI - 30 to < 35
        • 7.2.1.2. Class 2: BMI - 35 to < 40
        • 7.2.1.3. Class 3: BMI - > 40
      • 7.2.2. Global Genetic Obesity Drugs by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals pharmacy
        • 7.2.2.2. Retail Pharmacy
        • 7.2.2.3. Drug Stores
        • 7.2.2.4. Online Pharmacy
      • 7.2.3. Global Genetic Obesity Drugs by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Diagnostic Centres
        • 7.2.3.4. Government
      • 7.2.4. Global Genetic Obesity Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Genetic Obesity Drugs (Volume)
      • 7.3.1. Global Genetic Obesity Drugs by: Category (Volume)
        • 7.3.1.1. Class 1: BMI - 30 to < 35
        • 7.3.1.2. Class 2: BMI - 35 to < 40
        • 7.3.1.3. Class 3: BMI - > 40
      • 7.3.2. Global Genetic Obesity Drugs by: Distribution Channel (Volume)
        • 7.3.2.1. Hospitals pharmacy
        • 7.3.2.2. Retail Pharmacy
        • 7.3.2.3. Drug Stores
        • 7.3.2.4. Online Pharmacy
      • 7.3.3. Global Genetic Obesity Drugs by: End-User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Diagnostic Centres
        • 7.3.3.4. Government
      • 7.3.4. Global Genetic Obesity Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Australia
          • 7.3.4.2.6. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Genetic Obesity Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genetic Obesity Drugs: by Category(USD Million)
  • Table 2. Genetic Obesity Drugs Class 1: BMI - 30 to < 35 , by Region USD Million (2018-2023)
  • Table 3. Genetic Obesity Drugs Class 2: BMI - 35 to < 40 , by Region USD Million (2018-2023)
  • Table 4. Genetic Obesity Drugs Class 3: BMI - > 40 , by Region USD Million (2018-2023)
  • Table 5. Genetic Obesity Drugs: by Distribution Channel(USD Million)
  • Table 6. Genetic Obesity Drugs Hospitals pharmacy , by Region USD Million (2018-2023)
  • Table 7. Genetic Obesity Drugs Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 8. Genetic Obesity Drugs Drug Stores , by Region USD Million (2018-2023)
  • Table 9. Genetic Obesity Drugs Online Pharmacy , by Region USD Million (2018-2023)
  • Table 10. Genetic Obesity Drugs: by End-User(USD Million)
  • Table 11. Genetic Obesity Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 12. Genetic Obesity Drugs Clinics , by Region USD Million (2018-2023)
  • Table 13. Genetic Obesity Drugs Diagnostic Centres , by Region USD Million (2018-2023)
  • Table 14. Genetic Obesity Drugs Government , by Region USD Million (2018-2023)
  • Table 15. South America Genetic Obesity Drugs, by Country USD Million (2018-2023)
  • Table 16. South America Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 17. South America Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 18. South America Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 19. South America Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 20. South America Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 21. Brazil Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 22. Brazil Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 23. Brazil Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 24. Brazil Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 25. Brazil Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 26. Argentina Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 27. Argentina Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 28. Argentina Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 29. Argentina Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 30. Argentina Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 31. Rest of South America Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 33. Rest of South America Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 34. Rest of South America Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 35. Rest of South America Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 36. Asia Pacific Genetic Obesity Drugs, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 39. Asia Pacific Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 40. Asia Pacific Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 41. Asia Pacific Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 42. China Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 43. China Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 44. China Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 45. China Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 46. China Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 47. Japan Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 48. Japan Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 49. Japan Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 50. Japan Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 51. Japan Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 52. India Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 53. India Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 54. India Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 55. India Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 56. India Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 57. South Korea Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 58. South Korea Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 59. South Korea Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 60. South Korea Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 61. South Korea Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 62. Australia Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 63. Australia Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 64. Australia Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 65. Australia Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 66. Australia Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 72. Europe Genetic Obesity Drugs, by Country USD Million (2018-2023)
  • Table 73. Europe Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 74. Europe Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 75. Europe Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 76. Europe Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 77. Europe Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 78. Germany Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 79. Germany Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 80. Germany Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 81. Germany Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 82. Germany Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 83. France Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 84. France Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 85. France Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 86. France Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 87. France Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 88. Italy Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 89. Italy Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 90. Italy Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 91. Italy Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 92. Italy Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 93. United Kingdom Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 94. United Kingdom Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 95. United Kingdom Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 96. United Kingdom Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 97. United Kingdom Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 98. Netherlands Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 99. Netherlands Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 100. Netherlands Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 101. Netherlands Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 102. Netherlands Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 103. Rest of Europe Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 104. Rest of Europe Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 105. Rest of Europe Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 106. Rest of Europe Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 107. Rest of Europe Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 108. MEA Genetic Obesity Drugs, by Country USD Million (2018-2023)
  • Table 109. MEA Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 110. MEA Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 111. MEA Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 112. MEA Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 113. MEA Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 114. Middle East Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 115. Middle East Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 116. Middle East Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 117. Middle East Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 118. Middle East Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 119. Africa Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 120. Africa Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 121. Africa Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 122. Africa Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 123. Africa Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 124. North America Genetic Obesity Drugs, by Country USD Million (2018-2023)
  • Table 125. North America Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 126. North America Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 127. North America Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 128. North America Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 129. North America Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 130. United States Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 131. United States Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 132. United States Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 133. United States Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 134. United States Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 135. Canada Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 136. Canada Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 137. Canada Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 138. Canada Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 139. Canada Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 140. Mexico Genetic Obesity Drugs, by Type USD Million (2018-2023)
  • Table 141. Mexico Genetic Obesity Drugs, by Category USD Million (2018-2023)
  • Table 142. Mexico Genetic Obesity Drugs, by Drug USD Million (2018-2023)
  • Table 143. Mexico Genetic Obesity Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 144. Mexico Genetic Obesity Drugs, by End-User USD Million (2018-2023)
  • Table 145. Genetic Obesity Drugs Sales: by Category(K-Units)
  • Table 146. Genetic Obesity Drugs Sales Class 1: BMI - 30 to < 35 , by Region K-Units (2018-2023)
  • Table 147. Genetic Obesity Drugs Sales Class 2: BMI - 35 to < 40 , by Region K-Units (2018-2023)
  • Table 148. Genetic Obesity Drugs Sales Class 3: BMI - > 40 , by Region K-Units (2018-2023)
  • Table 149. Genetic Obesity Drugs Sales: by Distribution Channel(K-Units)
  • Table 150. Genetic Obesity Drugs Sales Hospitals pharmacy , by Region K-Units (2018-2023)
  • Table 151. Genetic Obesity Drugs Sales Retail Pharmacy , by Region K-Units (2018-2023)
  • Table 152. Genetic Obesity Drugs Sales Drug Stores , by Region K-Units (2018-2023)
  • Table 153. Genetic Obesity Drugs Sales Online Pharmacy , by Region K-Units (2018-2023)
  • Table 154. Genetic Obesity Drugs Sales: by End-User(K-Units)
  • Table 155. Genetic Obesity Drugs Sales Hospitals , by Region K-Units (2018-2023)
  • Table 156. Genetic Obesity Drugs Sales Clinics , by Region K-Units (2018-2023)
  • Table 157. Genetic Obesity Drugs Sales Diagnostic Centres , by Region K-Units (2018-2023)
  • Table 158. Genetic Obesity Drugs Sales Government , by Region K-Units (2018-2023)
  • Table 159. South America Genetic Obesity Drugs Sales, by Country K-Units (2018-2023)
  • Table 160. South America Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 161. South America Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 162. South America Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 163. South America Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 164. South America Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 165. Brazil Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 166. Brazil Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 167. Brazil Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 168. Brazil Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 169. Brazil Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 170. Argentina Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 171. Argentina Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 172. Argentina Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 173. Argentina Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 174. Argentina Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 175. Rest of South America Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 176. Rest of South America Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 177. Rest of South America Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 178. Rest of South America Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 179. Rest of South America Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 180. Asia Pacific Genetic Obesity Drugs Sales, by Country K-Units (2018-2023)
  • Table 181. Asia Pacific Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 182. Asia Pacific Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 183. Asia Pacific Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 184. Asia Pacific Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 185. Asia Pacific Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 186. China Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 187. China Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 188. China Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 189. China Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 190. China Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 191. Japan Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 192. Japan Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 193. Japan Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 194. Japan Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 195. Japan Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 196. India Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 197. India Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 198. India Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 199. India Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 200. India Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 201. South Korea Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 202. South Korea Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 203. South Korea Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 204. South Korea Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 205. South Korea Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 206. Australia Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 207. Australia Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 208. Australia Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 209. Australia Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 210. Australia Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 211. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 212. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 213. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 214. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 215. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 216. Europe Genetic Obesity Drugs Sales, by Country K-Units (2018-2023)
  • Table 217. Europe Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 218. Europe Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 219. Europe Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 220. Europe Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 221. Europe Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 222. Germany Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 223. Germany Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 224. Germany Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 225. Germany Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 226. Germany Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 227. France Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 228. France Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 229. France Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 230. France Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 231. France Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 232. Italy Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 233. Italy Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 234. Italy Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 235. Italy Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 236. Italy Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 237. United Kingdom Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 238. United Kingdom Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 239. United Kingdom Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 240. United Kingdom Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 241. United Kingdom Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 242. Netherlands Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 243. Netherlands Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 244. Netherlands Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 245. Netherlands Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 246. Netherlands Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 247. Rest of Europe Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 248. Rest of Europe Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 249. Rest of Europe Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 250. Rest of Europe Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 251. Rest of Europe Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 252. MEA Genetic Obesity Drugs Sales, by Country K-Units (2018-2023)
  • Table 253. MEA Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 254. MEA Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 255. MEA Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 256. MEA Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 257. MEA Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 258. Middle East Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 259. Middle East Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 260. Middle East Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 261. Middle East Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 262. Middle East Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 263. Africa Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 264. Africa Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 265. Africa Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 266. Africa Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 267. Africa Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 268. North America Genetic Obesity Drugs Sales, by Country K-Units (2018-2023)
  • Table 269. North America Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 270. North America Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 271. North America Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 272. North America Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 273. North America Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 274. United States Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 275. United States Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 276. United States Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 277. United States Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 278. United States Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 279. Canada Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 280. Canada Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 281. Canada Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 282. Canada Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 283. Canada Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 284. Mexico Genetic Obesity Drugs Sales, by Type K-Units (2018-2023)
  • Table 285. Mexico Genetic Obesity Drugs Sales, by Category K-Units (2018-2023)
  • Table 286. Mexico Genetic Obesity Drugs Sales, by Drug K-Units (2018-2023)
  • Table 287. Mexico Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2018-2023)
  • Table 288. Mexico Genetic Obesity Drugs Sales, by End-User K-Units (2018-2023)
  • Table 289. Company Basic Information, Sales Area and Its Competitors
  • Table 290. Company Basic Information, Sales Area and Its Competitors
  • Table 291. Company Basic Information, Sales Area and Its Competitors
  • Table 292. Company Basic Information, Sales Area and Its Competitors
  • Table 293. Company Basic Information, Sales Area and Its Competitors
  • Table 294. Company Basic Information, Sales Area and Its Competitors
  • Table 295. Company Basic Information, Sales Area and Its Competitors
  • Table 296. Company Basic Information, Sales Area and Its Competitors
  • Table 297. Company Basic Information, Sales Area and Its Competitors
  • Table 298. Company Basic Information, Sales Area and Its Competitors
  • Table 299. Genetic Obesity Drugs: by Category(USD Million)
  • Table 300. Genetic Obesity Drugs Class 1: BMI - 30 to < 35 , by Region USD Million (2025-2030)
  • Table 301. Genetic Obesity Drugs Class 2: BMI - 35 to < 40 , by Region USD Million (2025-2030)
  • Table 302. Genetic Obesity Drugs Class 3: BMI - > 40 , by Region USD Million (2025-2030)
  • Table 303. Genetic Obesity Drugs: by Distribution Channel(USD Million)
  • Table 304. Genetic Obesity Drugs Hospitals pharmacy , by Region USD Million (2025-2030)
  • Table 305. Genetic Obesity Drugs Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 306. Genetic Obesity Drugs Drug Stores , by Region USD Million (2025-2030)
  • Table 307. Genetic Obesity Drugs Online Pharmacy , by Region USD Million (2025-2030)
  • Table 308. Genetic Obesity Drugs: by End-User(USD Million)
  • Table 309. Genetic Obesity Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 310. Genetic Obesity Drugs Clinics , by Region USD Million (2025-2030)
  • Table 311. Genetic Obesity Drugs Diagnostic Centres , by Region USD Million (2025-2030)
  • Table 312. Genetic Obesity Drugs Government , by Region USD Million (2025-2030)
  • Table 313. South America Genetic Obesity Drugs, by Country USD Million (2025-2030)
  • Table 314. South America Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 315. South America Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 316. South America Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 317. South America Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 318. South America Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 319. Brazil Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 320. Brazil Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 321. Brazil Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 322. Brazil Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 323. Brazil Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 324. Argentina Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 325. Argentina Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 326. Argentina Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 327. Argentina Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 328. Argentina Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 329. Rest of South America Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 330. Rest of South America Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 331. Rest of South America Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 332. Rest of South America Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 333. Rest of South America Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 334. Asia Pacific Genetic Obesity Drugs, by Country USD Million (2025-2030)
  • Table 335. Asia Pacific Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 336. Asia Pacific Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 337. Asia Pacific Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 338. Asia Pacific Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 339. Asia Pacific Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 340. China Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 341. China Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 342. China Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 343. China Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 344. China Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 345. Japan Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 346. Japan Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 347. Japan Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 348. Japan Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 349. Japan Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 350. India Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 351. India Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 352. India Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 353. India Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 354. India Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 355. South Korea Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 356. South Korea Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 357. South Korea Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 358. South Korea Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 359. South Korea Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 360. Australia Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 361. Australia Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 362. Australia Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 363. Australia Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 364. Australia Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 365. Rest of Asia-Pacific Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 366. Rest of Asia-Pacific Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 367. Rest of Asia-Pacific Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 368. Rest of Asia-Pacific Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 369. Rest of Asia-Pacific Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 370. Europe Genetic Obesity Drugs, by Country USD Million (2025-2030)
  • Table 371. Europe Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 372. Europe Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 373. Europe Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 374. Europe Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 375. Europe Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 376. Germany Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 377. Germany Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 378. Germany Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 379. Germany Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 380. Germany Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 381. France Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 382. France Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 383. France Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 384. France Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 385. France Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 386. Italy Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 387. Italy Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 388. Italy Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 389. Italy Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 390. Italy Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 391. United Kingdom Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 392. United Kingdom Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 393. United Kingdom Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 394. United Kingdom Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 395. United Kingdom Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 396. Netherlands Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 397. Netherlands Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 398. Netherlands Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 399. Netherlands Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 400. Netherlands Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 401. Rest of Europe Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 402. Rest of Europe Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 403. Rest of Europe Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 404. Rest of Europe Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 405. Rest of Europe Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 406. MEA Genetic Obesity Drugs, by Country USD Million (2025-2030)
  • Table 407. MEA Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 408. MEA Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 409. MEA Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 410. MEA Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 411. MEA Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 412. Middle East Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 413. Middle East Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 414. Middle East Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 415. Middle East Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 416. Middle East Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 417. Africa Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 418. Africa Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 419. Africa Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 420. Africa Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 421. Africa Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 422. North America Genetic Obesity Drugs, by Country USD Million (2025-2030)
  • Table 423. North America Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 424. North America Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 425. North America Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 426. North America Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 427. North America Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 428. United States Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 429. United States Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 430. United States Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 431. United States Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 432. United States Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 433. Canada Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 434. Canada Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 435. Canada Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 436. Canada Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 437. Canada Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 438. Mexico Genetic Obesity Drugs, by Type USD Million (2025-2030)
  • Table 439. Mexico Genetic Obesity Drugs, by Category USD Million (2025-2030)
  • Table 440. Mexico Genetic Obesity Drugs, by Drug USD Million (2025-2030)
  • Table 441. Mexico Genetic Obesity Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 442. Mexico Genetic Obesity Drugs, by End-User USD Million (2025-2030)
  • Table 443. Genetic Obesity Drugs Sales: by Category(K-Units)
  • Table 444. Genetic Obesity Drugs Sales Class 1: BMI - 30 to < 35 , by Region K-Units (2025-2030)
  • Table 445. Genetic Obesity Drugs Sales Class 2: BMI - 35 to < 40 , by Region K-Units (2025-2030)
  • Table 446. Genetic Obesity Drugs Sales Class 3: BMI - > 40 , by Region K-Units (2025-2030)
  • Table 447. Genetic Obesity Drugs Sales: by Distribution Channel(K-Units)
  • Table 448. Genetic Obesity Drugs Sales Hospitals pharmacy , by Region K-Units (2025-2030)
  • Table 449. Genetic Obesity Drugs Sales Retail Pharmacy , by Region K-Units (2025-2030)
  • Table 450. Genetic Obesity Drugs Sales Drug Stores , by Region K-Units (2025-2030)
  • Table 451. Genetic Obesity Drugs Sales Online Pharmacy , by Region K-Units (2025-2030)
  • Table 452. Genetic Obesity Drugs Sales: by End-User(K-Units)
  • Table 453. Genetic Obesity Drugs Sales Hospitals , by Region K-Units (2025-2030)
  • Table 454. Genetic Obesity Drugs Sales Clinics , by Region K-Units (2025-2030)
  • Table 455. Genetic Obesity Drugs Sales Diagnostic Centres , by Region K-Units (2025-2030)
  • Table 456. Genetic Obesity Drugs Sales Government , by Region K-Units (2025-2030)
  • Table 457. South America Genetic Obesity Drugs Sales, by Country K-Units (2025-2030)
  • Table 458. South America Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 459. South America Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 460. South America Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 461. South America Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 462. South America Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 463. Brazil Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 464. Brazil Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 465. Brazil Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 466. Brazil Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 467. Brazil Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 468. Argentina Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 469. Argentina Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 470. Argentina Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 471. Argentina Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 472. Argentina Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 473. Rest of South America Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 474. Rest of South America Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 475. Rest of South America Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 476. Rest of South America Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 477. Rest of South America Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 478. Asia Pacific Genetic Obesity Drugs Sales, by Country K-Units (2025-2030)
  • Table 479. Asia Pacific Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 480. Asia Pacific Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 481. Asia Pacific Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 482. Asia Pacific Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 483. Asia Pacific Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 484. China Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 485. China Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 486. China Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 487. China Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 488. China Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 489. Japan Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 490. Japan Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 491. Japan Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 492. Japan Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 493. Japan Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 494. India Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 495. India Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 496. India Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 497. India Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 498. India Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 499. South Korea Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 500. South Korea Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 501. South Korea Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 502. South Korea Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 503. South Korea Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 504. Australia Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 505. Australia Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 506. Australia Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 507. Australia Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 508. Australia Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 509. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 510. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 511. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 512. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 513. Rest of Asia-Pacific Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 514. Europe Genetic Obesity Drugs Sales, by Country K-Units (2025-2030)
  • Table 515. Europe Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 516. Europe Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 517. Europe Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 518. Europe Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 519. Europe Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 520. Germany Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 521. Germany Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 522. Germany Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 523. Germany Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 524. Germany Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 525. France Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 526. France Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 527. France Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 528. France Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 529. France Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 530. Italy Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 531. Italy Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 532. Italy Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 533. Italy Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 534. Italy Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 535. United Kingdom Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 536. United Kingdom Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 537. United Kingdom Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 538. United Kingdom Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 539. United Kingdom Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 540. Netherlands Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 541. Netherlands Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 542. Netherlands Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 543. Netherlands Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 544. Netherlands Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 545. Rest of Europe Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 546. Rest of Europe Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 547. Rest of Europe Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 548. Rest of Europe Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 549. Rest of Europe Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 550. MEA Genetic Obesity Drugs Sales, by Country K-Units (2025-2030)
  • Table 551. MEA Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 552. MEA Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 553. MEA Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 554. MEA Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 555. MEA Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 556. Middle East Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 557. Middle East Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 558. Middle East Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 559. Middle East Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 560. Middle East Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 561. Africa Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 562. Africa Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 563. Africa Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 564. Africa Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 565. Africa Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 566. North America Genetic Obesity Drugs Sales, by Country K-Units (2025-2030)
  • Table 567. North America Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 568. North America Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 569. North America Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 570. North America Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 571. North America Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 572. United States Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 573. United States Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 574. United States Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 575. United States Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 576. United States Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 577. Canada Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 578. Canada Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 579. Canada Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 580. Canada Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 581. Canada Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 582. Mexico Genetic Obesity Drugs Sales, by Type K-Units (2025-2030)
  • Table 583. Mexico Genetic Obesity Drugs Sales, by Category K-Units (2025-2030)
  • Table 584. Mexico Genetic Obesity Drugs Sales, by Drug K-Units (2025-2030)
  • Table 585. Mexico Genetic Obesity Drugs Sales, by Distribution Channel K-Units (2025-2030)
  • Table 586. Mexico Genetic Obesity Drugs Sales, by End-User K-Units (2025-2030)
  • Table 587. Research Programs/Design for This Report
  • Table 588. Key Data Information from Secondary Sources
  • Table 589. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genetic Obesity Drugs: by Category USD Million (2018-2023)
  • Figure 5. Global Genetic Obesity Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Genetic Obesity Drugs: by End-User USD Million (2018-2023)
  • Figure 7. South America Genetic Obesity Drugs Share (%), by Country
  • Figure 8. Asia Pacific Genetic Obesity Drugs Share (%), by Country
  • Figure 9. Europe Genetic Obesity Drugs Share (%), by Country
  • Figure 10. MEA Genetic Obesity Drugs Share (%), by Country
  • Figure 11. North America Genetic Obesity Drugs Share (%), by Country
  • Figure 12. Global Genetic Obesity Drugs: by Category K-Units (2018-2023)
  • Figure 13. Global Genetic Obesity Drugs: by Distribution Channel K-Units (2018-2023)
  • Figure 14. Global Genetic Obesity Drugs: by End-User K-Units (2018-2023)
  • Figure 15. South America Genetic Obesity Drugs Share (%), by Country
  • Figure 16. Asia Pacific Genetic Obesity Drugs Share (%), by Country
  • Figure 17. Europe Genetic Obesity Drugs Share (%), by Country
  • Figure 18. MEA Genetic Obesity Drugs Share (%), by Country
  • Figure 19. North America Genetic Obesity Drugs Share (%), by Country
  • Figure 20. Global Genetic Obesity Drugs share by Players 2023 (%)
  • Figure 21. Global Genetic Obesity Drugs share by Players (Top 3) 2023(%)
  • Figure 22. Global Genetic Obesity Drugs share by Players (Top 5) 2023(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2023
  • Figure 26. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi (France) Revenue: by Geography 2023
  • Figure 28. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 30. Regeneron Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Regeneron Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 32. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 35. Gilead Sciences (United States) Revenue: by Geography 2023
  • Figure 36. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 37. Bristol Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 38. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 39. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 40. Rhythm Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 41. Rhythm Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 42. PreveCeutical Medical (Canada) Revenue, Net Income and Gross profit
  • Figure 43. PreveCeutical Medical (Canada) Revenue: by Geography 2023
  • Figure 44. Global Genetic Obesity Drugs: by Category USD Million (2025-2030)
  • Figure 45. Global Genetic Obesity Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 46. Global Genetic Obesity Drugs: by End-User USD Million (2025-2030)
  • Figure 47. South America Genetic Obesity Drugs Share (%), by Country
  • Figure 48. Asia Pacific Genetic Obesity Drugs Share (%), by Country
  • Figure 49. Europe Genetic Obesity Drugs Share (%), by Country
  • Figure 50. MEA Genetic Obesity Drugs Share (%), by Country
  • Figure 51. North America Genetic Obesity Drugs Share (%), by Country
  • Figure 52. Global Genetic Obesity Drugs: by Category K-Units (2025-2030)
  • Figure 53. Global Genetic Obesity Drugs: by Distribution Channel K-Units (2025-2030)
  • Figure 54. Global Genetic Obesity Drugs: by End-User K-Units (2025-2030)
  • Figure 55. South America Genetic Obesity Drugs Share (%), by Country
  • Figure 56. Asia Pacific Genetic Obesity Drugs Share (%), by Country
  • Figure 57. Europe Genetic Obesity Drugs Share (%), by Country
  • Figure 58. MEA Genetic Obesity Drugs Share (%), by Country
  • Figure 59. North America Genetic Obesity Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Sanofi (France)
  • Roche Holding AG (Switzerland)
  • Regeneron Pharmaceuticals (United States)
  • AstraZeneca (United Kingdom)
  • Gilead Sciences (United States)
  • Bristol Myers Squibb (United States)
  • Novo Nordisk (Denmark)
  • Rhythm Pharmaceuticals (United States)
  • PreveCeutical Medical (Canada)
Additional players considered in the study are as follows:
EraCal Therapeutics (Switzerland) , Phenomix Sciences (United States) , Antag Therapeutics (Denmark)
Select User Access Type

Key Highlights of Report


Feb 2024 240 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Genetic Obesity Drugs Market Quantitative research analysis
Global Genetic Obesity Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Genetic Obesity Drugs market are Pfizer (United States), Sanofi (France), Roche Holding AG (Switzerland), Regeneron Pharmaceuticals (United States), AstraZeneca (United Kingdom), Gilead Sciences (United States), Bristol Myers Squibb (United States), Novo Nordisk (Denmark), Rhythm Pharmaceuticals (United States) and PreveCeutical Medical (Canada), to name a few.
"Growing Prevalence of Epigenetics in Treatment of Obesity" is seen as one of major influencing trends for Genetic Obesity Drugs Market during projected period 2023-2030.

Know More About Global Genetic Obesity Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Buprenorphine Comprehensive Study by Application (Hospital, Clinic, Other), Side Effect (Sedation, Dizziness, Headache, Low blood pressure (hypotension), Slow breathing), Distribution Channel (Hospi...
$ 3450
Cholic Acid Comprehensive Study by Application (Liver Disease, Cyclosporine), Side Effect (Heartburn, Acid Reflux, Nausea, Diarrhea, Stomach Pain, Painful Urination, General Ill Feeling, Jaundice), D...
$ 3650
Chemotherapy Induced Lung Disease Treatment Comprehensive Study by Route Of Administration (Oral, Inject-able), Medication (Bleomycin, Carmustine, Busulfan, Cyclophosphamide), End User (Hospital, Cli...
$ 3500
Aripiprazole Drug Comprehensive Study by Type (Tablets, Orally Disintegrating Tablets, Oral Solution, Injection), End-users (Adult Patients, Pediatric Patients), Side Effects (Blurred Vision, Increas...
$ 3750
Cancer Biopsy Comprehensive Study by Type (Incisional Biopsy, Excisional Biopsy, Needle Biopsy), Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Other...
$ 3800
Chlorella Tablets Comprehensive Study by Type (Supplements, Vitamins), Sodium Content (Sodium-free, Low Sodium), Category (Vitamins & Supplements, Cleansing & Detox Supplements, Energy Supplements, A...
$ 3750